| Strategies to improve antimicrobial utilization with a special focus on developing countries B Godman, A Egwuenu, M Haque, OO Malande, N Schellack, S Kumar, ... Life 11 (6), 528, 2021 | 165 | 2021 |
| The implementation of managed entry agreements in Central and Eastern Europe: findings and implications A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ... Pharmacoeconomics 35, 1271-1285, 2017 | 163 | 2017 |
| Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications B Godman, B Wettermark, M Van Woerkom, J Fraeyman, ... Frontiers in pharmacology 5, 106, 2014 | 161 | 2014 |
| Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries … B Godman, M Haque, J McKimm, M Abu Bakar, J Sneddon, J Wale, ... Current medical research and opinion 36 (2), 301-327, 2020 | 156 | 2020 |
| Barriers for access to new medicines: searching for the balance between rising costs and limited budgets B Godman, A Bucsics, P Vella Bonanno, W Oortwijn, CC Rothe, A Ferrario, ... Frontiers in Public Health 6, 328, 2018 | 155 | 2018 |
| Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs RE Malmström, BB Godman, E Diogene, C Baumgärtel, M Bennie, ... Frontiers in pharmacology 4, 39, 2013 | 120 | 2013 |
| Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries T Bochenek, V Abilova, A Alkan, B Asanin, I de Miguel Beriain, Z Besovic, ... Frontiers in pharmacology 8, 942, 2018 | 118 | 2018 |
| Initiatives to reduce nonprescription sales and dispensing of antibiotics: findings and implications V Marković-Peković, N Grubiša, J Burger, L Bojanić, B Godman Journal of research in pharmacy practice 6 (2), 120-125, 2017 | 97 | 2017 |
| Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries B Godman, H McCabe, T D Leong, D Mueller, AP Martin, I Hoxha, ... Expert review of pharmacoeconomics & outcomes research 20 (1), 1-26, 2020 | 84 | 2020 |
| Are pharmacists’ good knowledge and awareness on antibiotics taken for granted? The situation in Albania and future implications across countries I Hoxha, A Malaj, B Kraja, S Bino, M Oluka, V Marković-Peković, ... Journal of global antimicrobial resistance 13, 240-245, 2018 | 80 | 2018 |
| Payers' views of the changes arising through the possible adoption of adaptive pathways M Ermisch, A Bucsics, P Vella Bonanno, F Arickx, A Bybau, T Bochenek, ... Frontiers in pharmacology 7, 305, 2016 | 71 | 2016 |
| Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications B Godman, A Hill, S Simoens, G Selke, I Selke Krulichová, ... Expert review of pharmacoeconomics & outcomes research 21 (4), 527-540, 2021 | 67 | 2021 |
| Essential to increase the use of generics in Europe to maintain comprehensive health care? B Godman, M Bennie, C Baumgärtel, L Sović-Brkičić, T Burkhardt, J Fürst, ... Farmeconomia. Health economics and therapeutic pathways 13 (3S), 5-20, 2012 | 67 | 2012 |
| The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures E Moorkens, B Godman, I Huys, I Hoxha, A Malaj, S Keuerleber, ... Frontiers in pharmacology 11, 591134, 2021 | 66 | 2021 |
| Dabigatran-a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs B Godman, RE Malmström, E Diogene, S Jayathissa, S McTaggart, T Cars, ... Frontiers in pharmacology 5, 109, 2014 | 63 | 2014 |
| Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): A narrative review and the implications Z Saleem, B Godman, F Azhar, AC Kalungia, J Fadare, S Opanga, ... Expert review of anti-infective therapy 20 (1), 71-93, 2022 | 59 | 2022 |
| Adaptive pathways: possible next steps for payers in preparation for their potential implementation P Vella Bonanno, M Ermisch, B Godman, AP Martin, J Van Den Bergh, ... Frontiers in pharmacology 8, 497, 2017 | 53 | 2017 |
| Self‐medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior V Marković‐Peković, N Grubiša Pharmacoepidemiology and drug safety 21 (10), 1130-1133, 2012 | 53 | 2012 |
| Pricing of oral generic cancer medicines in 25 European countries; findings and implications B Godman, A Hill, S Simoens, A Kurdi, J Gulbinovič, A Martin, A Timoney, ... Generics and Biosimilars Initiative Journal 8 (2), 49-70, 2019 | 51 | 2019 |
| Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions V Markovic-Pekovic, R Škrbić, B Godman, LL Gustafsson Expert review of pharmacoeconomics & outcomes research 12 (5), 661-671, 2012 | 51 | 2012 |
